| Year ended December 31, | 2024 vs. 2023 | 2023 vs. 2022 | |||||
| 2024 | 2023 | 2022 | Change | Change | Change | Change | |
| A$ | A$ | A$ | A$ | % | A$ | % | |
| (in thousands, except percentage data) | |||||||
| Revenue from contracts with customers | 9,351 | 5,391 | 3,727 | 3,960 | 73% | 1,664 | 45% |
| Cost of sales | - | - | - | - | - | ||
| Gross profit | 9,351 | 5,391 | 3,727 | 3,960 | 73% | 1,664 | 45% |
| Research and development costs | (82,582) | (47,566) | (32,402) | (35,016) | 74% | (15,164) | 47% |
| Selling and marketing expenses | (136) | (118) | - | (18) | 15% | (118) | * |
| Manufacturing and distribution costs | (4) | (76) | (12) | 72 | (95%) | (64) | 533% |
| General and administration costs | (92) | (127) | - | 35 | (28%) | (127) | * |
| Other (gains)/losses (net) | - | - | 10 | - | (10) | (100%) | |
| Operating profit/(loss) | (73,463) | (42,496) | (28,677) | (30,967) | 73% | (13,819) | 48% |
| Other (gains)/losses (net) | - | - | (10) | - | 10 | (100%) | |
| Depreciation and amortization | - | 45 | 40 | (45) | (100%) | 5 | 13% |
| Adjusted EBITDA | (73,463) | (42,451) | (28,647) | (31,012) | 73% | (13,804) | 48% |
| Precision Medicine | Therapeutics | Manufacturing Solutions | Total segment | |||||||||||||
| 2022 | A$’000 | A$’000 | A$’000 | A$’000 | ||||||||||||
| Revenue from contracts with customers | 156,369 | 3,727 | - | 160,096 | ||||||||||||
| Cost of sales | (65,170) | - | - | (65,170) | ||||||||||||
| Gross profit | 91,199 | 3,727 | - | 94,926 | ||||||||||||
| Research and development costs | (48,285) | (32,402) | - | (80,687) | ||||||||||||
| Selling and marketing expenses | (36,313) | - | - | (36,313) | ||||||||||||
| Manufacturing and distribution costs | (2,564) | (12) | (1,373) | (3,949) | ||||||||||||
| General and administration costs | (23,807) | - | (775) | (24,582) | ||||||||||||
| Other losses (net) | (17,496) | 10 | - | (17,486) | ||||||||||||
| Operating profit/(loss) | (37,266) | (28,677) | (2,148) | (68,091) | ||||||||||||
| Other losses (net) | 17,496 | (10) | - | 17,486 | ||||||||||||
| Depreciation and amortization | 4,679 | 40 | 21 | 4,740 | ||||||||||||
| Adjusted earnings before interest, tax, depreciation and amortization | (15,091) | (28,647) | (2,127) | (45,865) | ||||||||||||
| Year ended December 31, | 2024 vs. 2023 | 2023 vs. 2022 | |||||
| 2024 | 2023 | 2022 | Change | Change | Change | Change | |
| A$ | A$ | A$ | A$ | % | A$ | % | |
| (in thousands, except percentage data) | |||||||
| Revenue from contracts with customers | 771,106 | 496,738 | 156,369 | 274,368 | 55% | 340,369 | 218% |
| Cost of sales | (270,821) | (188,157) | (65,170) | (82,664) | 44% | (122,987) | 189% |
| Gross profit | 500,285 | 308,581 | 91,199 | 191,704 | 62% | 217,382 | 238% |
| Research and development costs | (111,348) | (80,327) | (48,285) | (31,021) | 39% | (32,042) | 66% |
| Selling and marketing expenses | (84,562) | (49,991) | (36,313) | (34,571) | 69% | (13,678) | 38% |
| Manufacturing and distribution costs | (7,807) | (7,601) | (2,564) | (206) | 3% | (5,037) | 196% |
| General and administration costs | (42,800) | (30,979) | (23,807) | (11,821) | 38% | (7,172) | 30% |
| Other (gains)/losses (net) | (8,909) | (35,138) | (17,496) | 26,229 | (75%) | (17,642) | 101% |
| Operating profit/(loss) | 244,859 | 104,545 | (37,266) | 140,314 | 134% | 141,811 | * |
| Other (gains)/losses (net) | 8,909 | 35,138 | 17,496 | 26,229 | (75%) | 17,642 | 101% |
| Depreciation and amortization | 5,573 | 5,511 | 4,679 | 62 | 1% | 832 | 18% |
| Adjusted EBITDA | 259,341 | 145,194 | (15,091) | 114,147 | 79% | 160,285 | * |
| Precision Medicine | Therapeutics | Manufacturing Solutions | Total segment | |||||||||||||
| 2023 | A$’000 | A$’000 | A$’000 | A$’000 | ||||||||||||
| Revenue from contracts with customers | 496,738 | 5,391 | 418 | 502,547 | ||||||||||||
| Cost of sales | (188,157) | - | - | (188,157) | ||||||||||||
| Gross profit | 308,581 | 5,391 | 418 | 314,390 | ||||||||||||
| Research and development costs | (80,327) | (47,566) | (644) | (128,537) | ||||||||||||
| Selling and marketing expenses | (49,991) | (118) | - | (50,109) | ||||||||||||
| Manufacturing and distribution costs | (7,601) | (76) | (2,192) | (9,869) | ||||||||||||
| General and administration costs | (30,979) | (127) | (3,516) | (34,622) | ||||||||||||
| Other losses (net) | (35,138) | - | - | (35,138) | ||||||||||||
| Operating profit/(loss) | 104,545 | (42,496) | (5,934) | 56,115 | ||||||||||||
| Other losses (net) | 35,138 | - | - | 35,138 | ||||||||||||
| Depreciation and amortization | 5,511 | 45 | 231 | 5,787 | ||||||||||||
| Adjusted earnings before interest, tax, depreciation and amortization | 145,194 | (42,451) | (5,703) | 97,040 | ||||||||||||
| 2024 | 2023 | 2022 | ||||||||||
| A$’000 | A$’000 | A$’000 | ||||||||||
| Therapeutics | ||||||||||||
| TLX591 (Phase 3) | 44,879 | 23,975 | 15,518 | |||||||||
| TLX250, TLX101 (Phase 2) | 12,404 | 10,441 | 8,241 | |||||||||
| TLX66, TLX300 (Phase 1) | 10,900 | 4,534 | 1,605 | |||||||||
| Pre-clinical research and innovation | 14,399 | 8,616 | 7,038 | |||||||||
| Total Therapeutics R&D | 82,582 | 47,566 | 32,402 | |||||||||
| Precision Medicine | ||||||||||||
| Illuccix, TLX591-CDx (Commercial) | 14,725 | 10,565 | 10,611 | |||||||||
| Pixclara, Zircaix, Gozellix (Pre-commercial) | 88,754 | 59,605 | 31,667 | |||||||||
| Pre-clinical research and innovation | 7,869 | 10,157 | 6,007 | |||||||||
| Total Precision Medicine R&D | 111,348 | 80,327 | 48,285 | |||||||||
| Total product development R&D | 193,930 | 127,893 | 80,687 | |||||||||
| Manufacturing Solutions | ||||||||||||
| Other research and development projects | 707 | 644 | - | |||||||||
| Total Manufacturing Solutions R&D | 707 | 644 | - | |||||||||
| Total research and development costs | 194,637 | 128,537 | 80,687 | |||||||||
